MedTrace Logo

Single Dose PG102 in Patients With Active Psoriatic Arthritis

NCT00787137 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2010-10-26

Study results available
· View outcomes & findings →

Summary

The primary objective is to evaluate the safety and tolerability of a single intravenous dose of PG102 in patients with psoriatic arthritis. The secondary objectives are to evaluate how PG102 moves around the body and to explore its effects on the disease.

Conditions

  • Arthritis, Psoriatic

Interventions

DRUG

PG102

A single intravenous infusion

DRUG

Placebo comparator

Phosphate-buffered saline

Sponsors & Collaborators

  • PanGenetics UK Limited

    lead INDUSTRY

Principal Investigators

  • Nemanja Damjanov, MD PhD · Institute of Rheumatology, Belgrade, Serbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2010-04-30
Completion
2010-05-31

Countries

  • Serbia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00787137 on ClinicalTrials.gov